Neoadjuvant Pertuzumab Biosimilar HLX11 versus Reference Pertuzumab for Early-Stage or Locally Advanced Breast Cancer: A Phase III Equivalence Trial

帕妥珠单抗 医学 曲妥珠单抗 肿瘤科 多西紫杉醇 生物仿制药 临床终点 内科学 乳腺癌 佐剂 置信区间 紫杉烷 新辅助治疗 临床试验 随机对照试验 临床研究阶段 危险系数 相对风险
作者
Jin Zhang,Jinhai Zhu,Yaping Yang,Dong Song,Tao Huang,Xiaopeng Ma,莫钦国,Xiaobo Du,Chunwei Xie,Yu Tang Ren,Fan Li,Bo Zhang,Xujuan Wang,Zhaofeng Niu,Hongsheng Li,Peifen Fu,Qingyuan Zhang,Min-Ying Li,Xiaoyu Liu,王启堂
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:: OF1-OF11
标识
DOI:10.1158/1078-0432.ccr-26-1604
摘要

PURPOSE: This randomized, double-blind phase 3 equivalence study aimed to evaluate the similarity of neoadjuvant pertuzumab biosimilar HLX11 versus reference pertuzumab plus trastuzumab and docetaxel for human epidermal growth factor receptor 2-positive, hormone receptor-negative early-stage or locally advanced breast cancer (BC). PATIENTS AND METHODS: Eligible patients were randomly assigned (1:1) to receive 4 cycles of neoadjuvant HLX11 (HLX11 arm) or European Union-sourced pertuzumab, plus trastuzumab and docetaxel (EU-pertuzumab arm). Patients in the respective arms received adjuvant HLX11 plus trastuzumab or were re-randomized (1:1) to receive HLX11 or EU-pertuzumab plus trastuzumab. The primary endpoint was blinded independent central review (BICR)-assessed total pathological complete response (tpCR) rate. RESULTS: In total, 908 patients were randomized to the HLX11 (n = 454) or EU-pertuzumab arm (n = 454); 192 patients in HLX11 arm received adjuvant HLX11; 200 patients in EU-pertuzumab arm were re-randomized to receive adjuvant HLX11 (n = 100) or EU-pertuzumab (n = 100). BICR-assessed tpCR rate (95% confidence interval [CI]) was 46.3% (41.6%-51.0%) and 45.8% (41.2%-50.5%), respectively. The equivalence criteria were met, with relative risk of tpCR (90% CI) of 1.01 (0.90-1.14) and relative difference (95% CI) of 0.47% (-5.99%-6.92%). No clinically meaningful differences were observed in other efficacy endpoints, safety, pharmacokinetics (PK), or immunogenicity. In the adjuvant phase, switching from EU-pertuzumab to HLX11 led to no notable differences in safety, PK, or immunogenicity. CONCLUSIONS: Compared with EU-pertuzumab, neoadjuvant HLX11 demonstrated a similar tpCR rate and no clinically meaningful differences in other efficacy endpoints, safety, PK, or immunogenicity in BC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Lumous完成签到,获得积分10
1秒前
1秒前
领导范儿的应助被聚乙二醇采纳,获得10
1秒前
1秒前
1秒前
wanttt完成签到,获得积分10
1秒前
STEAM发布了新的文献求助10
2秒前
kay发布了新的文献求助10
3秒前
好人一生平安完成签到,获得积分10
3秒前
3秒前
3秒前
Yasong发布了新的文献求助10
3秒前
silentyw完成签到,获得积分10
3秒前
3秒前
lishixi完成签到,获得积分20
4秒前
YY完成签到,获得积分10
4秒前
lb完成签到,获得积分10
4秒前
过江春雷完成签到,获得积分10
4秒前
4秒前
dadaTwgdh完成签到,获得积分20
4秒前
178完成签到,获得积分10
5秒前
fantasy的应助被mmmm采纳,获得10
5秒前
且听风吟发布了新的文献求助10
5秒前
HiJ发布了新的文献求助10
5秒前
爱笑果汁完成签到 ,获得积分10
5秒前
5秒前
HiJ发布了新的文献求助10
5秒前
6秒前
千寻完成签到,获得积分10
6秒前
重要莹发布了新的文献求助10
6秒前
6秒前
包凡之发布了新的文献求助10
6秒前
zzz完成签到,获得积分10
6秒前
科研通AI2S的应助被HebingTang采纳,获得10
6秒前
6秒前
7秒前
7秒前
赘婿的应助被聚乙二醇采纳,获得10
7秒前
完美世界的应助被monkey采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315